OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence the outcomes and treatment decisions. Patients diagnosed with indolent NHLs (follicular lymphoma [FL] or marginal zone lymphoma [MZL]) can achieve a median survival of 10 to 20 years, and relative 10-year survival rates of over 60%. However, patients with aggressive NHLs (diffuse large B-cell lymphoma [DLBCL] or mantle cell lymphoma [MCL]) can generally expect lower median survival rates, with the relative 10-year survival reported to be less than 50%.

For the purposes of this report, GlobalData focuses on the four most prevalent B-cell NHL subtypes: FL, MZL, DLBCL and MCL. The global market is defined to include sales of drugs aimed at treatment of those four subtypes in patients 30 years and older across the 7MM, which is comprised of the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. The forecast includes the sale of agents in first-line, relapsed/refractory, and maintenance settings. GlobalData anticipates a major driver of market growth to be the steady increase in uptake of Imbruvica to treat MCL, and its anticipated expansion into FL, MZL, and DLBCL treatment settings over the forecast period.


Overview of NHL, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.

Topline NHL drug market revenue from 2014–2024. Annual cost of therapy (ACOT) and major product sales in first-line, relapsed/refractory, and maintenance treatment settings during the forecast period are included.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, and R&D strategies for the NHL market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

Analysis of the current and future market competition in the global NHL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the NHL marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2014–2024)?

What research and development (R&D) strategies will companies leverage to compete in the future NHL marketplace?

Which pipeline products are poised to make a major clinical and commercial impact?

What clinical and commercial factors are likely to influence NHL drug uptake in the US and 5EU (France, Germany, Italy, Spain, and the UK) and Japan (7MM)?

Bristol-Myers Squibb
Seattle Genetics

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures



2.2Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Pathophysiology of Indolent and Aggressive B-Cell NHL


4Disease Management


4.2Diagnostic Classification

4.2.1Follicular Lymphoma

4.2.2Marginal Zone Lymphoma

4.2.3Diffuse Large B-Cell Lymphoma

4.2.4Mantle Cell Lymphoma

4.3Treatment Overview

4.3.1Follicular Lymphoma

4.3.2Marginal Zone Lymphoma

4.3.3Diffuse Large B-Cell Lymphoma

4.3.4Mantle Cell Lymphoma


5.1Disease Background

5.2Risk Factors and Comorbidities

5.3Global Trends




5.4Forecast Methodology

5.4.1Sources Used

5.4.2Sources Not Used

5.4.3Forecast Assumptions and Methods

5.5Epidemiological Forecast for B-Cell NHL (2014–2024)

5.5.1Follicular Lymphoma

5.5.2Marginal Zone Lymphoma

5.5.3Diffuse Large B-Cell Lymphoma

5.5.4Mantle Cell Lymphoma


5.6.1Epidemiological Forecast Insight

5.6.2Limitations of the Analysis

5.6.3Strengths of the Analysis

6Current Treatment Options


6.2Product Profiles – Major Brands

6.2.1Imbruvica (ibrutinib)

6.2.2Revlimid (lenalidomide)

6.2.3Rituxan (rituximab)

6.2.4Treanda (bendamustine)

6.2.5Velcade (bortezomib)

6.2.6Zevalin (ibritumomab tiuxetan)

6.2.7Zydelig (idelalisib, GS-1101, CAL-101)

7Unmet Needs Assessment and Opportunity Analysis


7.2Unmet Needs Analysis

7.2.1Unmet Need: Therapies That Prolong OS or PFS and Delay Relapse in Indolent NHL Patients

7.2.2Unmet Need: Safe and More Tolerable Front-Line Agents for Indolent NHL Patients

7.2.3Unmet Need: Prolonged Survival Rates for MCL Patients

7.2.4Unmet Need: Improved Cure Rate and Survival for DLBCL Patients after Front-Line Therapy

7.2.5Unmet Need: Predictive and Prognostic Molecular Biomarkers

7.3Opportunity Analysis

7.3.1Opportunity: More Cost-Effective Therapies

7.3.2Opportunity: Improved Consolidation/Maintenance Therapies for Follicular NHL Patients

7.3.3Opportunity: Novel Agents for Front-Line DLBCL and MCL Therapy

7.3.4Opportunity: Development of Novel Therapies for NHL Patients

8Research and Development Strategies


8.1.1Targeting Multiple NHL Subtypes and Lines of Therapy to Capture the Greatest Patient Share

8.1.2Inhibiting New Targets in Relapsed/Refractory NHL Patients

8.1.3Novel Approaches to NHL Treatment

8.1.4Developing Novel Drugs in Combination with Rituxan to Replace Chemoimmunotherapy Regimens

8.1.5Developing Second-Generation Therapies to Replace the Established Standards of Care at the End of Patent Life

8.1.6Companies Collaborating on Investigator-Sponsored, Early-Stage Trials to Minimize Up-Front Risk

8.1.7Introducing New Routes of Drug Delivery to Improve Patient Convenience

8.2Clinical Trial Design

8.2.1Indolent and Aggressive B-Cell NHL

8.2.2Clinical Endpoints

8.2.3Comparator Arms

9Pipeline Assessment


9.2Promising Drugs in Clinical Development

9.2.1Afinitor (everolimus)

9.2.2Arzerra (ofatumumab)

9.2.3Copanlisib (BAY 80-6946)

9.2.4Duvelisib (IPI-145)

9.2.5Gazyva (obinutuxumab)

9.2.6Opdivo (nivolumab)

9.3Innovative Early-Stage Approaches

9.3.1Adcetris (brentuximab vedotin)

9.3.2Blinatumomab (AMG-103)



9.3.5Kyprolis (carfilzomib)

9.3.6Y-90 Epratuzumab

9.3.7Chimeric Antigen Receptor T-Cell Therapies

10Pipeline Valuation Analysis

10.1Clinical Benchmarking of Key Pipeline Drugs

10.1.1Indolent NHL

10.1.2Aggressive NHL

10.2Commercial Benchmarking of Key Pipeline Drugs

10.3Competitive Assessment

10.4Top-Line, 10-Year Forecast








11.4Forecasting Methodology

11.4.1NHL Patient Population Segmentation

11.4.2Percentage of Drug-Treated Patients

11.4.3Drugs Included in Each Therapeutic Class

11.4.4Launch and Patent Expiry Dates

11.4.5General Pricing Assumptions

11.4.6Individual Drug Assumptions

11.4.7Generic and Biosimilar Erosion

11.5Primary Research

11.5.1Physicians and Specialists Included in This Study

11.5.2Online Survey of High Prescribing Physicians

11.6About the Authors



11.6.3Therapy Area Director

11.6.4Global Director of Therapy Analysis and Epidemiology

11.6.5Global Head of Healthcare

11.7About GlobalData


Frequently asked questions

OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024 in real time.

  • Access a live OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.